SCHEMBL10029321

SCHEMBL10029321

O=S(=O)(NCC12CC3CC(CC(C3)C1)C2)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
TSHR P16473 1/20 0.43
EPHX2 P34913 7/20 0.41
HSD17B10 Q99714 1/20 0.40
CA2 P00918 1/20 0.36
KMT2A Q03164 1/20 0.35
P2RX7 Q99572 1/20 0.35
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
EPHX1 P07099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19042237 0.89 ALDH1A1 (0.41) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL12256395 0.86 ALDH1A1 (0.43) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL9609292 0.83 ALDH1A1 (0.42) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL19042250 0.83 ALDH1A1 (0.39) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL19042235 0.82 CA2 (0.43) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL9609350 0.82 ALDH1A1 (0.41) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL18572485 0.80 ALDH1A1 (0.37) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL12452699 0.80 ALDH1A1 (0.40) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL16065514 0.79 ALDH1A1 (0.39) ALDH1A1TSHREPHX2HSD17B10CA2
SCHEMBL16519734 0.79 HSD17B10 (0.40) ALDH1A1TSHREPHX2HSD17B10CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230359119-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-09 US disclosed
US-11754926-B2 Method of forming resist pattern, resist composition and method of producing the same TOKYO OHKA KOGYO CO., LTD. (JP) 2023-09-12 US disclosed
US-20220127225-A1 ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-04-28 US disclosed
US-20170184962-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-06-29 US disclosed
US-20170184964-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-06-29 US disclosed
US-20170184963-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-06-29 US disclosed
US-8980527-B2 Pattern forming process and resist compostion SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-8921027-B2 Radiation-sensitive resin composition JSR CORPORATION (JP) 2014-12-30 US disclosed
US-8921027-B2 Radiation-sensitive resin composition JSR CORPORATION (JP) 2014-12-30 US disclosed
US-20130183621-A1 PATTERN FORMING PROCESS AND RESIST COMPOSTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2013-07-18 US disclosed
US-20120082936-A1 RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2012-04-05 US disclosed
US-20080206668-A1 NEGATIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127225-A1 ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS CACNA1F, SLC6A5, IDUA ALDH1A1 3860/4885TSHR 4292/4885EPHX2 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.